Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/22/2018 |
| Start Date: | September 10, 2018 |
| End Date: | July 2021 |
| Contact: | Reza Nezafat, Ph.D |
| Email: | Rnezafat@bidmc.harvard.edu |
| Phone: | 617-667-1747 |
This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a
method of detecting early signs of damage to the heart that can be associated with adjuvant
therapy of anthracycline (doxorubicin)-based combination chemotherapy followed by treatment
with herceptin (trastuzumab for the treatment of (HER+) breast cancer.
method of detecting early signs of damage to the heart that can be associated with adjuvant
therapy of anthracycline (doxorubicin)-based combination chemotherapy followed by treatment
with herceptin (trastuzumab for the treatment of (HER+) breast cancer.
HER 2 breast cancer that has been shown to respond well to adjuvant therapy of doxorubicin
followed by trastuzumab. One of the side effects observed in women receiving this treatment
is heart complications in which the heart muscle is weakened and no longer able to pump
sufficient amounts of blood throughout the body. This complication can lead to the following
symptoms: shortness of breath on exertion, swollen ankles and feet, lack of energy and a
reduced capacity to carry out day-to-day activities.
This research study is focused on identifying the early signs of such heart complications
using CMR, which may allow preventative treatment options to be made available in future.
followed by trastuzumab. One of the side effects observed in women receiving this treatment
is heart complications in which the heart muscle is weakened and no longer able to pump
sufficient amounts of blood throughout the body. This complication can lead to the following
symptoms: shortness of breath on exertion, swollen ankles and feet, lack of energy and a
reduced capacity to carry out day-to-day activities.
This research study is focused on identifying the early signs of such heart complications
using CMR, which may allow preventative treatment options to be made available in future.
Inclusion Criteria:
- age > 18 years
- have histologic diagnosis of HER2+ breast carcinoma
- are scheduled to receive adjuvant therapy consisting of doxorubicin followed by
trastuzumab
- able to give informed consent.
Exclusion Criteria:
- any prior cardiovascular disease
- atrial fibrillation
- baseline screening echo LVEF ≤ 50
- contraindication to contrast CMR including eGFR <30 mls/min/1.73m2
- prior chemotherapy or radiotherapy
- uncontrolled serious concurrent illness
- pregnancy or breast feeding
We found this trial at
1
site
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Reza Nezafat, Ph.D
Phone: 617-667-1747
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
